Napolitano, Daniele
 Distribuzione geografica
Continente #
AS - Asia 1.136
NA - Nord America 1.048
EU - Europa 720
SA - Sud America 313
AF - Africa 36
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.256
Nazione #
US - Stati Uniti d'America 997
SG - Singapore 510
BR - Brasile 251
CN - Cina 230
IT - Italia 214
VN - Vietnam 166
FR - Francia 104
DE - Germania 93
SE - Svezia 87
GB - Regno Unito 44
FI - Finlandia 43
JP - Giappone 40
CA - Canada 32
KR - Corea 29
ID - Indonesia 27
IE - Irlanda 25
IN - India 25
AR - Argentina 22
HK - Hong Kong 22
IQ - Iraq 20
RU - Federazione Russa 18
BD - Bangladesh 16
ZA - Sudafrica 15
MX - Messico 14
PL - Polonia 14
ES - Italia 13
NL - Olanda 13
TR - Turchia 12
EC - Ecuador 11
AT - Austria 10
CO - Colombia 10
IL - Israele 7
SA - Arabia Saudita 6
SI - Slovenia 6
UA - Ucraina 6
LT - Lituania 5
MA - Marocco 5
CH - Svizzera 4
PT - Portogallo 4
UY - Uruguay 4
VE - Venezuela 4
AZ - Azerbaigian 3
BO - Bolivia 3
CL - Cile 3
EG - Egitto 3
JO - Giordania 3
KE - Kenya 3
PY - Paraguay 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AU - Australia 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
JM - Giamaica 2
LV - Lettonia 2
LY - Libia 2
MY - Malesia 2
PH - Filippine 2
PS - Palestinian Territory 2
UZ - Uzbekistan 2
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BG - Bulgaria 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CW - ???statistics.table.value.countryCode.CW??? 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GD - Grenada 1
GR - Grecia 1
HR - Croazia 1
HU - Ungheria 1
IR - Iran 1
KW - Kuwait 1
MD - Moldavia 1
MK - Macedonia 1
MM - Myanmar 1
NG - Nigeria 1
NP - Nepal 1
OM - Oman 1
PE - Perù 1
PK - Pakistan 1
QA - Qatar 1
RO - Romania 1
RS - Serbia 1
SN - Senegal 1
SR - Suriname 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TN - Tunisia 1
TW - Taiwan 1
Totale 3.256
Città #
Singapore 310
San Jose 151
Ashburn 130
Chandler 70
Rome 58
Ho Chi Minh City 54
New York 53
Beijing 51
The Dalles 51
Hefei 50
Los Angeles 50
Hanoi 48
Tokyo 37
Munich 31
Frankfurt am Main 30
Lauterbourg 29
Seoul 28
São Paulo 26
Dublin 23
Helsinki 23
Milan 22
Hong Kong 21
Jakarta 21
Kent 16
Montreal 16
Council Bluffs 15
Dallas 13
Marseille 13
Turku 13
North Bergen 12
Paris 12
Boardman 11
Boston 11
Houston 11
Poplar 11
Brooklyn 9
Denver 9
Moscow 9
Nuremberg 9
Warsaw 9
Belo Horizonte 8
Da Nang 8
Johannesburg 8
St Louis 8
Baghdad 7
Mexico City 7
Najaf 7
Orem 7
Princeton 7
Stockholm 7
Bogotá 6
Can Tho 6
Falkenstein 6
Guarulhos 6
Lappeenranta 6
Macerata 6
Porto Alegre 6
Rio de Janeiro 6
Santa Clara 6
Seattle 6
Toronto 6
Amsterdam 5
Atlanta 5
Buffalo 5
Cagliari 5
Caxias do Sul 5
Chicago 5
Hyderabad 5
Mumbai 5
Phoenix 5
Tel Aviv 5
Appignano 4
Brasília 4
Bremen 4
Dhaka 4
Düsseldorf 4
Hải Dương 4
Manaus 4
Pune 4
Quito 4
Roubaix 4
Salvador 4
Scandicci 4
Thái Nguyên 4
Zurich 4
Amman 3
Baku 3
Biên Hòa 3
Buenos Aires 3
Bắc Ninh 3
Calgary 3
Cape Town 3
Chelsea 3
Chennai 3
Cremona 3
Elk Grove Village 3
Haiphong 3
Hillsboro 3
Istanbul 3
Joinville 3
Totale 1.857
Nome #
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 155
Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study 144
The role of inflammatory bowel disease nurses for patients on biologic therapy during the COVID-19 pandemic 143
Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients 135
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 126
Knowledge of Diagnostic and Therapeutic Aspects of IBD Among Nurses Working in Digestive Endoscopy: A Nationwide Italian Survey 121
Novel Insights into the Pathogenesis of Inflammatory Bowel Diseases 120
Serial Fecal Microbiota Infusions via Colonoscopy for Active Ulcerative Colitis: A Feasibility, Safety, and Translational Monocentric Italian Study 119
Gut Microbiota Signatures Are Associated With Psychopathological Profiles in Patients With Ulcerative Colitis: Results From an Italian Tertiary IBD Center 118
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 118
Addressing Nutritional Knowledge Gaps in Inflammatory Bowel Disease: A Scoping Review 113
The awareness of the IBD nurse position among patients from an Italian tertiary IBD centre 111
Validity and Reliability of the Self-Care of Chronic Illness Inventory in Patients Living With Inflammatory Bowel Disease 109
Self-care in patients affected by inflammatory bowel disease and caregiver contribution to self-care (IBD-SELF): a protocol for a longitudinal observational study 109
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 107
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 106
Changes in the intestinal microbiota in patients with a major depressive episode and ulcerative colitis 104
Knowledge of perianal Crohn's disease among nurses in an Italian tertiary centre 101
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study 98
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study 94
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study 91
Patient satisfaction with nursing care during biological therapy for inflammatory bowel disease: An observational study 91
Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study 88
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy 84
Evaluation of factors associated with trust in telemedicine in patients with inflammatory bowel disease during COVID-19 pandemic: a multicenter cross-sectional survey 79
The educational role of IBD nurses in Italy in vaccinations: do not miss the moment for COVID-19 75
Nonmedical switch of anti-TNF-α biosimilars has no major clinical, pharmacokinetic and psychological impact on patients with IBD - the SAFER Study 74
Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission 72
The inflammatory bowel disease care manager: Italian state of the art 69
Adaptation of the European Crohn's Colitis Organisation quality of care standards to Italy: The Italian Group for the study of inflammatory bowel disease consensus 63
Psychological Assessment and Psychosocial Outcomes in Bariatric Surgery Candidates: A Retrospective Study 61
The role of resilience in mitigating depression and anxiety in patients with inflammatory bowel diseases 42
Exploring the Mediating Role of Self-Efficacy in the Relationship Between Caregiver Contribution and Resilience in Inflammatory Bowel Disease 35
Patient Satisfaction with IBD Undergoing Colonoscopy: A Multicenter Cross-Sectional Study 29
Knowledge of perianal Crohn's disease among nurses in an Italian tertiary centre 4
Totale 3.308
Categoria #
all - tutte 12.525
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.525


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213 0 0 0 0 0 0 0 0 0 0 1 2
2021/202258 1 0 0 2 1 0 0 3 0 18 16 17
2022/2023222 36 28 10 32 18 14 22 7 18 6 15 16
2023/2024251 6 40 16 19 11 35 21 7 17 21 24 34
2024/2025771 8 11 63 22 41 24 59 24 87 88 178 166
2025/20262.003 251 160 158 308 328 115 305 114 128 136 0 0
Totale 3.308